undamentalytics Newsletter
Sign in

Spero Therapeutics, Inc. cash flow statement

In fiscal 2025, Spero Therapeutics, Inc.'s operations generated −$12.6m of cash; it spent $0 on capital projects, leaving free cash flow of −$12.6m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−29−39−40−50−86−64−8−33−23−1320
Depreciation and amortisation0001111000—
Stock-based pay01345998844
Capital spending10200000000
Free cash flow−30−39−42−50−86−64−8−33−23−1320
Free cash flow after stock pay−30−41−45−54−91−74−17−41−31−1716
Shares issued———16138—00——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: EDIT vs SPROSPRO vs STROOCUL vs SPRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Spero Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Spero Therapeutics, Inc.